FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.
Our mission is to bring health solutions to Canadian cancer patients, physicians, caregivers and the many partners and stakeholders that support them. Our goal is to accelerate unique and important treatments that meaningfully enhance life.
A Canadian Life Sciences Company
Canada has an abundance of world-leading health research and a strong and rapidly-growing industry to translate that research into new therapeutics. FORUS is a Canada-based pharmaceutical company and partner that brings these and other therapeutic innovations to patients.
Bring global patient-ready products to Canadians.
Identify and develop partnerships with early-stage Canadian health innovators to advance Canadian innovations locally, and abroad.
FORUS has secured an exclusive Canadian distribution agreement with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for the commercialization of XPOVIO® (selinexor), an FDA-approved cancer medicine for adults with multiple myeloma; the second most common blood cancer and lymphoma. Every year, 3,400 Canadians are diagnosed with multiple myeloma, and sadly 1,600 die from the disease.
FORUS will build its pipeline with Canadian assets in discovery and development as well as other innovative products either in late stage-clinical development or with regulatory authorizations in jurisdictions outside of Canada.
FORUS is founded by experienced Canadian bioentrepreneur, Kevin Leshuk. Mr. Leshuk brings over 25 years of experience in the pharmaceutical industry. He and the FORUS founding team have delivered significant financial returns, and since 2009, achieved 12 Health Canada approvals, including five in multiple myeloma.